Hanseniase neural primaria: revisao sistematica by Garbino, Jose Antonio et al.
397
view and review
DOI: 10.1590/0004-282X20130046
Primary neural leprosy: systematic review
Hanseníase neural primária: revisão sistemática
José Antonio Garbino1, Wilson Marques Jr2, Jaison Antonio Barreto1, Carlos Otto Heise3, Márcia Maria Jardim 
Rodrigues4, Sérgio L. Antunes4, Cleverson Teixeira Soares1, Marcos Cesar Floriano5, José Augusto Nery4, 
Maria Angela Bianconcini Trindade6, Noêmia Barbosa Carvalho7, Nathália Carvalho de Andrada7, 
Amilton Antunes Barreira2, Marcos da Cunha Lopes Virmond1
This study is a systematic review on the current concepts 
of primary neural leprosy (PNL). The following online data-
bases were consulted: MEDLINE, Lilacs/SciELO, and Embase. 
Selected studies were classified based on the degree of recom-
mendation and levels of scientific evidence according to the 
“Oxford Centre for Evidence-based Medicine”(A,B,C and D). 
In an editorial of the International Journal of Leprosy, 
Wade1(D) mentioned the results of the International 
Symposium on the Leprosy Classification, which recognized 
the polyneuritic form of leprosy.
The assessment of 20,000 patients with leprosy, from five 
continents, during a 28-year-period, showed that neuritic 
manifestations, mainly specific paresthesia, are common, 
being presented as mononeuritis or multiple mononeuritis, 
which may precede cutaneous lesion in several months2(C).
Therefore, suspected of PNL are those patients that present 
single or multiple mononeuropathy and polyneuropathy (con-
fluent mononeuropathies) as a first manifestation of leprosy, 
without other identified etiology and skin lesions.
PREVALENCE 
PNL prevalence is low, but it can be overestimated when 
the investigation of the skin lesion is not complete3,4(C), as 
well as when there is no adequate differential diagnosis4(D).
ABSTRACT
The authors proposed a systematic review on the current concepts of primary neural leprosy by consulting the following online databases: MEDLINE, 
Lilacs/SciELO, and Embase. Selected studies were classified based on the degree of recommendation and levels of scientific evidence according 
to the “Oxford Centre for Evidence-based Medicine”. The following aspects were reviewed: cutaneous clinical and laboratorial investigations, i.e. skin 
clinical exam, smears, and biopsy, and Mitsuda’s reaction; neurological investigation (anamnesis, electromyography and nerve biopsy); 
serological investigation and molecular testing, i.e. serological testing for the detection of the phenolic glycolipid 1 (PGL-I) and the polymerase 
chain reaction (PCR); and treatment (classification criteria for the definition of specific treatment, steroid treatment, and cure criteria).
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RESUMO
Os autores propuseram-se a realizar uma revisão sistemática em conceitos atuais sobre a hanseníase neural primária, consultando as 
seguintes bases bibliográficas on-line: MEDLINE, Lilacs/SciELO e Embase. Os estudos selecionados foram classificados conforme o grau de 
recomendação e o nível de evidência científica de acordo com o “Oxford Centre for Evidence-based Medicine”. Os seguintes temas foram revisados: 
investigações clínica e laboratorial cutâneas, ou seja, exame, esfregaço e biópsia de pele e reação de Mitsuda; investigação neurológica 
(anamnese, eletroneuromiografia e biópsia de nervo); investigação sorológica e testes moleculares, ou seja, testes sorológicos para detecção 
de um glicolipídio fenólico e reação de cadeia de polimerase (PCR) e tratamento (critérios de classificação para definição de tratamento 
específico, tratamento com esteroides e critérios de cura).
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An epidemiologic study carried out in India followed 
8,000 individuals during five years. Eight hundred patients 
were identified with leprosy, being 106 cases of PNL. The annual 
incidence was of 8.2:10005(C).
Dongre et al.6(C), also in India, studied 11,581 individuals, 
and found 494 PNL cases (4.3%) and 143 (1.2%) with spe-
cific nonvisible anesthetic lesions, totalizing 5.5% of patients 
without visible skin lesions.
There are no similar data in Brazil, but in one reference 
center from São Paulo State, including 162 patients that 
underwent nerve biopsy between 1985 and 2005, 34 cases of 
PNL were diagnosed, that is, less than two per year4(D).
DIFFERENTIAL DIAGNOSIS
The differential diagnosis should target causes for 
mononeuropathy and multiple neuropathy, including 
inflammatory (collagenosis and non-systemic vasculitis); 
metabolic (diabetes, hypothyroidism and dysfunction of the 
hypophysis); infectious (syphilis and Aids); traumatic and 
postural (acute and chronic compressions); congenital or 
hereditary (syringomyelia/syringobulbia, congenital insen-
sibility to pain, hereditary neuropathy with susceptibility to 
pressure), and tumoral (neural sheath tumors and others) 
ones. The histopathological analysis of the nerve must be 
able to generate parameters to establish likely diagnosis4(C).
OBJECTIVE
The aim of this review was to elaborate recommendations 
and standardizing procedures towards the diagnosis of PNL, 
based on scientific evidences.
DIAGNOSIS
Clinical investigation of the primary neural leprosy 
suspected cases
In PNL, there is absence of cutaneous lesions, and slit skin 
smear of suspected areas can also be negative for M. leprae. 
Follow-up of 182 PNL cases along 36 months showed that 
29 patients (15.8%) developed skin lesion7(C).
Peripheral neuropathy may precede skin lesions from 
15.0 to 35.0% of PNL cases7,8(C). Follow-up of such patients 
is always necessary9(C) because leprosy reaction may appear 
on many of them, redefining the diagnosis10(C).
If there is clinical suspicion of PNL, detailed dermatological 
assessment and follow-up should be done even after starting 
the specific treatment for leprosy. Onset of reaction or skin 
lesion confirms the diagnosis and reclassifies the form of leprosy, 
consequently helping on the prevention of nerve damages.
Diagnosis value of the skin bacilloscopy on 
suspicion of primary neural leprosy
Patients that are suspected of PNL show peripheral neu-
ropathy, without other likely etiology and skin involvement 
clinically nor laboratorially identifiable1,4,10(D). For example, 
in a series of PNL suspected cases studied between 1991 and 
2004, only patients with negative skin bacilloscopy were 
included11-13(C). Indeed, this is fundamental even in the 
absence of visible skin lesions, as well as the bacilloscopy 
index (BI)14(D). The areas where bacilli are most likely to be 
found are the cold regions of the skin: ear lobes, posterior 
region of the elbows and anterior one of the knees, where 
loss of sensitivity is more frequent15(B). It is however important 
to note that bacilloscopy is positive only after a load 104 ba-
cilli/gram of tissue is reached. In this sense, false negative 
smears can be expected in borderline patients16(C).
The BI study must be conducted on the ear lobes, posterior 
region of the elbows and anterior one of the knees, before 
directing the patient to reference centers or specialized con-
sultation. When the BI is greater than zero, the PNL diagnosis 
is invalidated and classified as multi-bacillary leprosy. 
Value of the skin biopsy on the primary neural 
leprosy diagnosis
The diagnosis confirmation of the PNL is challenging, 
once two cardinal signs of leprosy (skin lesions and smears 
for acid fast resistant bacilli) are absent.
In 208 patients with PNL confirmed after neural biopsy, 
the cutaneous one was performed on hypo/anesthetic areas 
(133 patients) and on preserved sensitivity regions, near to the 
affected nerve (63 patients), founding compatible histopath-
ological alterations on 58.6% of the cases. Also considering the 
non-specific inflammatory alterations, the positivity rose to 
81.1%. The sensitivity for nerve biopsy (75.9%) is greater than 
that for skin biopsies (58.6%), even though the latter is less 
invasive17(B). Some authors did not found histopathological 
alterations on the anesthetic areas without skin lesions11(B), 
while others demonstrated that the skin biopsy of such areas 
was abnormal from 31.0 to 33.3% of the cases13,18(C), reaching 
up to 64% when the non-specific inflammatory alterations 
were also considered18(C).
In suspected cases of PNL, skin biopsy on hypoesthetic 
areas may help the diagnosis; however, in their absence, 
cutaneous biopsy on the regions near the affected nerve may 
help the diagnosis. The absence of cutaneous alterations in 
the histology does not exclude the diagnosis. As it is less 
invasive than the neural, skin biopsy is recommended as the 
first option.
Interpretation of Mitsuda’s test and its meaning in 
primary neural leprosy diagnosis
Mitsuda’s test is performed with an intradermal inoculation 
of a solution of killed by heat M. leprae bacilli. Reading is done 
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after four weeks, being positive if there is a papule greater 
than 5 mm or ulceration. The histopathology may show gran-
ulomatous reaction similar to the tuberculoid form19(C). Most 
populations in endemic areas present positive responses, not 
getting sick, or can develop the tuberculoid form, which is not 
transmissible20(B). Therefore, Mitsuda’s test helps in the clas-
sification and prognosis21(B).
In a population with 137 individuals with PNL, who 
undergone Mitsuda’s test investigation, it was observed that 
93 (70%) of those presenting positive reaction to such evaluation, 
only 16 were borderline lepromatous (BL) or lepromatous (LL) 
on the histopathology from the damaged cutaneous nerve or 
skin with sensory impairment. Out of 44 (30%) individuals 
with negative test, 28 (64%) were LL or BL on histopa-
thology. Mitsuda’s test must be judiciously used to classify 
PNL in paucibacillary (PB) or multibacillary (MB)17(B), along 
with the clinical and histological findings. Isolated, the test is 
not useful for the PNL diagnosis18(C).
In case of neuritis in patients with PNL, the positivity of the 
test ranges from 57.1 to 100.0%13,22(C). The positivity of Mitsuda’s 
reaction in 5 LL/BL cases reinforces the need for the histo-
logical analysis of the reaction23(C). Though being of a poor 
diagnostic value, Mitsuda’s reaction is useful for assessing on 
the immunological and prognostic status23(C). Subjects with 
positive Mitsuda’s test and low antibodies titles usually 
correspond to the tuberculoid form (TT) or borderline-tubercu-
loid (BT), while those with negative and high antibodies titles 
correspond to the MB Group. The test shows higher indurations 
diameter in PB patients23(C). 
Mitsuda’s test, together with the clinical, serological, and 
histopathological data, helps in the operational classifications 
of patients with PNL.
Neurological manifestations of leprosy
The assessment of the patient with PNL must follow the same 
steps of that with multiple mononeuropathy, and the neurological 
approach must be as wide as possible.
Van Brakel and Khawas24(B) studied 396 new cases, finding 
motor function impairment in 96 and sensory impairment 
in 116. The most common damages were the sensory 
component of the posterior tibial (21.0%), motor component 
of the ulnar (20.0%), sensory component of the ulnar (17.0%), 
sensory component of the median (8.8%), and motor component 
of the lateral popliteal (4.8%).
Ramadan et al.25(C) assessed 40 patients, being the ulnar 
nerve the most frequent damaged and the claw hand the 
most common disability. All the sensory modalities were 
affected: superficial and deep sensitivities. However, deep 
pressure was altered only on late cases. The sensory impair-
ment predominated over the motor. 
Jardim et al.26(C) assessed 49 patients with PNL, observing 
paresthesias in 55.0%, motor impairment in 24.0%, neural pain 
in 12.0%, and sensory loss in 8.0%. Multiple mononeuropathy 
was observed in 61.0%, mononeuropathy in 33.0% and only 
three patients (6%) presented polyneuropathy. Sensory 
nerves were more compromised than the motor ones, and 
the ulnar nerve was the most frequent affected. 
Van Brakel et al.27(B) assessed 303 patients with leprosy, 
observing good concordance between the monofilament and 
the other tests of sensory function, validating the monofilaments 
as the standard form of screening. Heat sensitivity was more 
accurate than the cold, and there was a positive correlation 
to the touch.
Jardim et al.28(C) studied 19 patients with PNL, and clinically 
they found sensory and motor losses in 78.9% of the cases, 
followed by neural thickening (68.4%) and pain (42.1%). In 
other study, Jardim et al.29(B) assessed 24 patients with PNL. 
The main manifestations were sensory (21/24), predominating 
paresthesias (17/21), pain (2/21) or hypoesthesia (2/21). 
On three patients, the initial manifestation was motor, being 
amyotrophy in one of them and muscle weakness in the others. 
In the first exam of these patients, before treatment, the 
following were observed: acrocyanosis (71.0%), neural thick-
ening (21.88%), muscle weakness (88.0%), and sensory 
impairment (83.0%). 
Dos Santos15(B) analyzed 20 patients with leprosy, and 
observed that the sensory loss predominated on the following 
regions: posterior of the elbow, posterior of the forearm all 
the way to the back of the hand, on the palm of the hand, on the 
knee, and on the side strip of the leg down to the distal 
region on the foot and plantar region. The posterior region 
of the elbow, specially, had high diagnostic value. The sensi-
tivity to pain was involved earlier, being more extensive than 
the tactile one. The author concluded that the sensory loss 
in leprosy has a pattern of preferential topographic distribu-
tion that contributes to the characterization and diagnosis of 
such neuropathy15(B).
Existing data is contradictory, and the methodology and 
objective of the studies are heterogeneous. Seemingly, the neu-
ropathy of the PNL has a predominantly sensory involvement. 
Sensitivity to heat and pain are the most compromised, 
and in general, it has an asymmetric pattern of multiple 
mononeuropathy. The nerves with higher frequency of 
impairment, in the analyzed series, were the ulnar, the su-
perficial radial, the sural, the superficial fibular, and the tibial 
in the sensory modality. The less frequently involved nerves 
were the common fibular and median.
Nerve conduction studies: diagnostic of sensibility 
and specificity 
During the course of the disease, a patient with leprosy 
neuropathy may present many physiopathological processes 
in different periods, depending on the clinical classification, 
evolution, and treatment. In this connection, nerve conduction 
studies (NCS) are a sensitive method for the investiga-
tion of PNL13,28,30(C). The most common pattern observed is 
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the multiple mononeuropathy (79.0%), with occurrence of 
isolated mononeuropathy (10.5%) or distal polyneuropathy 
(10.5%)28(C). The Program of the International Federation of 
Anti-Leprosy Associations (ILEP) denominated ILEP Nerve 
Function Impairment in Reaction (INFIR) assessed 268 patients 
with positive bacilloscopy or at least six skin lesions, and it 
was observed reduction of: sensory nerve action potential 
(SNAP) amplitudes (sural 65.0%, radial 57.0%, ulnar 40.0%, and 
median 36.0%); sensory conduction velocity (sural 49.0%, 
radial 34.0%, ulnar 25.0%, and median 21.0%); compound 
motor action potential amplitudes — CMAP ( fibular 34.0%, 
median 25.0%, and ulnar 23.0%): and motor conduction 
velocity (ulnar 36.0%, fibular 16.0%, and median 15.0%)31(B). 
Another study from India, with 357 patients, presented alterations 
on sensory nerve conduction in 88.0% and on motor conduction 
in 75.0%32(C). 
Andrade33(C) assessed 77 cases of leprosy with neuropathy. 
The most prevalent pattern was the asymmetric sensory-motor 
neuropathy in 61.0%, with focal reduction of conduction ve-
locity; 19.0% presented asymmetric and axonal sensory-motor 
neuropathy, without focal reduction detected; and 12.0%, 
asymmetric sensory-motor neuropathy, with predominance 
of sensory onset. Capadia et al.34(B) detected neurophysiologic 
alterations on the 21 patients with PNL, and 18 presented 
sensory-motor abnormalities. Other studies have confirmed such 
findings25,35-37(C). There is prominence of demyelinating neuropa-
thy of the ulnar nerve at the elbow in 55.0% of the cases34,36(C). 
All these studies emphasize the asymmetric and multifo-
cal impairments. 
The neurophysiological evaluation is more sensitive 
than the clinical examination for the detection of nerve 
impairment31(B),38(C), and the presence of abnormalities is 
frequent, even on nonenlarged nerves37(C). Patients with-
out clinical involvement presented abnormalities on NCS in 
40.0% of the cases38(C).
Though the needle electromyography expands the informa-
tion obtained by NCS, there is no evidence that this technique 
increases the sensitivity of the test38(C). 
Besides the strictly diagnostic aspects, NCS are useful on the 
follow-up, mainly in patients with types 1 and 2 reactions39(C). 
NCS are abnormal even earlier than the threshold of heat 
sensation40(B). While evaluating the distribution of the neurop-
athy, NCS also help in choosing the nerve to be biopsied13(C).
The NCS should be performed on patients with suspicion 
of PNL, in order to characterize the neuropathy and help with 
the choice of the nerve to be biopsied. During and after treatment, 
they help in the follow-up of the neuropathy and diagnosis of 
acute or subacute reactions on nerves.
Sensibility and specificity of the serological testing 
for the detection of phenolic glycolipid 1 antibodies 
The phenolic glycolipid 1 (PGL-1) is M. leprae specific. 
Antibodies, mainly the IgM class, are useful for the evaluation 
of infection, and its level shows a strong correlation with 
the bacillary load41(C). They are detected by enzyme assay 
(ELISA), passive hemagglutination test (PHA), hemagglutination 
on gelatin particle (MLPA) and rapid tests for field use, such 
as ML-Flow, which demonstrated 91% of concordance with the 
ELISA method (95%CI 0.70–0.84)42(B).
Additionally, the ML-Flow test showed positive results 
in 97.4% of MB patients; 40.0% on PB, 28.6% on household 
contacts, and 9.8% in the Control Group. Therefore, the sen-
sibility of the test related to the correct classification of the 
patients was 97.4% for MB. The specificity of the method, 
based on Control Group results, was 90.2%42(B).
At a recent systematic review, it was mentioned a 78.0% 
average sensibility for MB patients, though 23% of PB and 
also apparently healthy contacts may present positive serology on 
low levels43(B), demonstrating that the test may help in the 
classification of patients, correlating with antibody level and 
bacteriological index. In this review, there was no significant 
difference between the ELISA test and the rapid methods of 
antibodies detection. The positivity of the tests becomes 
higher with the increase on the number of affected nerves and 
skin lesions. 
The serology may also be useful in the follow-up of neu-
ropathy and in monitoring MB patients’ treatment as well as 
individuals under relapse risk. Subjects with more than one 
compromised nerve trunk have four times greater chances to be 
seropositive (OR=2.4), even with few or no cutaneous lesions44(B).
The antibody levels are significantly higher on patients 
with leprosy than on the Control Group45(C). 
In another study, the results of the IgM anti-PGL-1 
antibodies tested by ELISA were compared on four popu-
lations: nontreated patients, MB subjects treated for 12 months 
with multidrug therapy (MDT), MB ones treated for 24 
months with MDT, and PB individuals treated for six months 
with MDT. Statistically significant differences were found 
(p<0.01) in the IgM anti-PGL-1 values: between nontreated 
patients and the MB patients treated for 12 months (6.95±1.35 
versus 2.78±0.69), and between the nontreated patients and 
MB ones treated for 24 months (12.53±2.02 versus 2.62±0.79). 
There was no significant difference between nontreated 
patients and PB treated ones46(B). These data indicate that 
the monitoring of anti-PGL-1 levels during MDT may be a sen-
sitive instrument for the evaluation of the treatment efficacy.
The serology for IgM anti-PGL-1 detection is useful for 
evaluating the M. leprae infection level and monitoring the 
bacillary load. However, it should not be the only criterion 
for the diagnosis of leprosy, as it can be false negative in some 
MB cases. Additionally, on endemic areas, this technique 
makes no distinction between infection and disease. Patients 
diagnosed with leprosy with titers higher than 0.15 on ELISA 
ND-O-BSA (natural disaccharide – octyl – bovine serum 
albumine) should be treated with MDT for MB patients.
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Nerve biopsy on primary neural leprosy
The sensibility of neural biopsy (75.9%) is greater than skin 
biopsy (58.6%), although the nerve one is quite invasive17(B). 
Some authors have demonstrated that skin biopsy of areas with 
sensory alteration present histopathological evidences of 
leprosy at a proportion that varies from 31.0 to 50.0%18,26,28(C), 
reaching up to 64.0%, if nonspecific inflammatory alterations 
are considered18(C).
Sixty-seven patients with PNL underwent biopsy of the 
dorsal cutaneous branch of the ulnar, sural, and superficial 
fibular nerves; 16.0% of them evidenced bacilli alcohol acid 
resistant (BAAR) and the molecular diagnosis based on the 
biopsy was positive in 47.0%26 (C). 
A total of 33 patients suspected of PNL were followed clin-
ically from 1994 to 2004. All of them underwent nerve biopsy, 
29 sural nerves and four dorsal cutaneous branch of the ulnar 
nerve. The biopsy confirmed leprosy in 11 patients (33.3%)13 (C). 
In 19 patients with PNL and nerve biopsies, morphologi-
cal alteration was found in all biopsied nerves, although BAAR 
was found only in three cases. In six people, molecular diag-
nosis was made by the polymerase chain reaction (PCR)28 (C).
In one subject with superficial fibular neuropathy, the 
diagnosis was made based on the presence of BAAR on 
the biopsy of such nerve47(C). 
One male patient presented multiple floating saccular 
formations in the subcutaneous region on the projection of 
several nerves. The biopsy exam of the superficial radial nerve 
lead to the diagnosis of BT leprosy, based on granulomatous 
infiltrate of epithelial cells, lymphocytes and caseous necrosis, 
that is, a nerve abscess48(C).
Cases with clinic-neurological and/or electrophysiological 
evidence of PNL may have an indication for nerve biopsy. 
It must be performed exclusively on sensory nerves or their 
branches with unequivocal impairment. In this context, the 
sural nerve should be the first choice.
Histopathological patterns found on nerve biopsy 
and the indication of semi-thin section
On the histopathological study of the nerve, the hema-
toxylin-eosin, the Fite-Faraco and the immunohistochemistry, 
which is the anti-BCG antibody13(C), are the routine staining tech-
niques. The evaluation of the histological sections may show 
the same patterns of leprosy observed on skin lesions, as well 
as an unspecific framework, which include: discrete chronic 
inflammatory infiltrate, nongranulomatous, epi, peri and 
endoneurial fibrosis, and hyalinization of the nerve. Bacilli or 
bacterial antibodies may also be detected on Schwann’s cells 
or inside endoneurial granulomas. On late stages, it is pos-
sible to observe an extensive fibrosis and hyalinization 
of the endoneurium and a complete destruction of the 
nerve architecture13,26,28 (C). 
The microscopy of semi-thin sections (0.5 μm thick) shows 
the reduction of the number of large and small myelinated 
fibers, demyelination, axonal degeneration, besides allowing 
greater accuracy in the visualization of the sub-perineurial edema 
and thickening of perineurium. However, it is not more sen-
sible than the staining of Fite-Faraco for BAAR detection. 
The microscopy of semi-thin sections does not increase the 
sensitivity of diagnosis of specific leprosy alteration, but it 
contributes to detect unspecific alterations, helping with the 
differential diagnosis28(C).
The samples histopathology of hypoesthesic skin areas of 
patients with PNL, particularly on regions supplied by clinic 
or electrophysiological impaired nerves, may show the 
presence of perineurial inflammatory infiltrate around 
cutaneous nerve filament in 31.0% of the cases, which con-
firms the diagnosis without the need of nerve biopsy18(C).
The diagnosis of certainty and the very probable diagnosis 
will be performed when the following aspects are observed: 
inflammatory infiltrate composed by vacuolated macro-
phages (Virchow cells), containing BAAR inside macrophages 
and Schwann cells, accompanied by sparse lymphocytes, and 
granulomatous inflammatory infiltrate with epithelioid cells, 
occupying the endoneurium and absence of BAAR on biopsy. 
The probable and possible diagnoses will show: lymphocytic 
and macrophagic inflammatory infiltrates without differ-
entiation for epithelioid cells, not even for Virchow cells, 
occupying the endoneurium around vessels permeating 
nerve fibers and absence of BAAR, and epi, peri and endo-
neural fibrosis, edema of the subperineurial space with an 
increase of the mononuclear lymphocytic cells (lymphocytes 
and macrophages). Such findings may be accompanied by a 
numeric loss of large and small myelinated fibers. 
Nerve biopsy must always be indicated when there is 
suspicion of PNL without other confirmatory findings by 
other exams. Semi-thin sections study is a supporting procedure 
allowing the detection of unspecific alterations that can 
strengthen the diagnosis of possibility and help in differ-
ential diagnosis.
Diagnostic value of polymerase chain reaction
There are few studies regarding the diagnostic value of 
PCR. Martinez et al.49(B) amplified the 85 kDA gene in 69 samples 
of skin biopsy of leprosy patients. MB patients were all positive, 
and among the PB ones the detection rate varied from 62.5 
to 79.2%. Jardim et al.26(C) performed PCR on material extracted 
from nerves and the results were positive in 16 out of 20 BAAR 
negative patients; among them, four out of 16 had normal biopsy.
Bezerra da Cunha et al.50(C) studied the PCR on nerve 
samples of 40 BT and 18 TT patients. Out of 38 BAAR negative 
biopsies (20 BT and 18 TT), it was positive on 14 (12 BT and 2 TT).
The certainty diagnostic of PNL through histopathology 
depends on the presence of BAAR. PCR adds sensitivity on 
BAAR negative cases. It adds sensitivity to routine histological 
methods. Every nerve sample harvested due to PNL suspicion 
must have a nonfixed fraction stored in dry ice for PCR study.
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TREATMENT
Classification criteria in primary neural leprosy 
cases to define specific treatment
At the International Symposium for Leprosy Classification 
in 1952, there was no consensus about PNL. For some, it was a 
special form of leprosy, for others the matter was considered 
uncertain1(D). The Madrid and Indian classifications10(D) 
considered that PNL could be within any of the following 
clinical forms: undetermined, tuberculoid, and dimorphous 
or virchowian. 
The PNL ranking depends on the neurological, immuno-
logical, and histopathological findings. It is considered PB 
when there is only one damaged nerve, and MB when there 
is more than one12,51(C).
The immunological evaluation depends on Mitsuda’s test 
and on the IgM anti-PGL-1 serology. In the PB patients that 
present positive Mitsuda, a negative serology is expected, 
and for MB, the opposite10(C)11,44(B).
Nerve histopathology may define PB (tuberculoid) or 
MB (borderline-lepromatous, borderline-borderline and 
borderline-tuberculoid)13,52(C) forms.
In the absence of histopathological abnormalities on nerve 
biopsy or of biopsy, the PNL classification should be done on 
the basis of clinical and immunological criteria, the number 
of compromised nerves and the result of Mitsuda’s reaction.
Cure criteria for primary neural leprosy
The World Health Organization (WHO) recommended 
that MDT must be given according to the operational classifi-
cation (PB or MB)51(D). The patient is released from treatment 
at the end of the doses prescribed for each group14. Some 
experts believe MDT has the disadvantage of not eliminating the 
mycobacterial antibodies from the nerves, which may maintain 
neuritis and cause future disabilities throughout time, even 
after the patient has been cured. Despite the improvement 
with MDT, some patients show persisting activity, with reactions 
and relapse53(C).
An alternative regimen with dapsone, clofazimine and 
rifampicin for six months for PB and MB showed a poor 
response under clinical (35.0 against 77.0% on MDT-WHO) 
and histopathological points of view (50.0% when compared 
with MDT preconized by WHO)54(B). 
Relapse is defined by the presence of new signs and symp-
toms and new BAAR detection on the skin or nerve biopsy. 
Relapse rate varies between 1.0% and more than 40.0% depending 
on the treatment regimen, follow-up duration, and if it was 
determined by physical exam, skin smear, or biopsy53(C). 
The patient with PNL is considered healed after receiving 
the MDT regimen adequate to the clinical form. However, the 
individual should be oriented to return if there is worsening of 
neural function or in the appearance of new skin lesions. 
Studies on prophylactic treatment with steroids 
combined to specific therapy on primary neural 
leprosy
The preventive treatment of neuritis with steroids together 
with MDT is still discussed, even in MB forms. In a random-
ized study, an initial dose of 20 mg/day versus placebo was 
used, and then it was progressively reduced in four months. 
The authors observed the reduction of new reactions inci-
dence during steroid use and a decrease in the sensory loss. 
However, these effects did not persist after the interruption 
of the steroid treatment55(B). 
In a study where an initial dose of 40 mg/day was used 
and reduced in up to 12 months to 5 mg/day, with repetition 
of treatment if reactions appeared, it was observed impairment 
prevention and improvement of motor function during drug 
administration, but the sensory impairment did not show 
any function recovery56(C).
The electrophysiological assessment of 24 PB PNL patients 
with neural loss, treated with an initial dose of 60 mg/day 
orally, which was progressively reduced for six months, 
presented significant sensory and motor improvements in 
the study period29(B).
Random clinical trial including 21 MB and PB patients, with 
electrophysiological follow-up during a six-month treatment 
period, showed that initial doses of 1 mg/kg/day presented the 
same effectiveness as the 2 mg/kg/day dosage, if introduced 
within less than three months after the first symptoms57(B). 
The adverse effects were more pronounced when the initial 
dosage was 2 mg/kg/day.
In cases of PNL there are no evidences on how long reactions 
will happen after the MDT58(D). An exploratory cohort study, with 
594 MB and PB patients, concluded that MB patients reduce to a 
third the incidence of reactions in four years after the end of MDT, 
and PB patients after two years59(B).
PNL patients must have a follow-up plan during and after 
MDT, in order to monitor neurological loss, for at least two 
years considering that most of the patients are PB. Under the 
presence of active neuropathy, by clinic or by electrophysiology, 
it is indicated to start treatment with steroids, with doses 
of 1 mg/kg/day. If this picture is found at the moment of 
diagnosis, the treatment should be initiated with prednisone, 
along with MDT.
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